ACC House Call: PARTNER 3 Takeaways
An interventional cardiologist shares perspective on what the new two-year TAVR findings mean for him and colleagues.
New PARTNER 3 findings reported at the ACC.20 Together with Word Congress of Cardiology (ACC/WCC) Scientific Sessions this weekend showed transcatheter aortic valve replacement (TAVR) procedure via SAPIEN-3 was associated with a 37% reduction in death, stroke, or cardiovascular rehospitalization in low-risk surgery patients with aortic stenosis versus standard surgery.
The two-year data, presented by Michael J. Mack, MD, cardiothoracic surgeon at Baylor Scott and White, complemented previous PARTNER trial successes observed in older, higher-risk patients with aortic stenosis with an understanding of its sustained benefit in younger patients with lesser surgery risk. The trial also compounded on one-year findings in low-risk patients, and led to discussion as to what ten-year outcomes data will look like in the SAPIEN-3-treated patients—a trial goal already established by investigators.
But what does this newest data mean for interventional cardiology?
In an interview with HCPLive®, Ashish Pershad, MD, an interventional cardiologist at Banner — University Medicine Heart Institute, shared his perspective on what the two-year, low-risk PARTNER 3 findings indicate, what questions still remain from the trial program, and what he hopes to learn from eventual ten-year findings.
